GLP‑1 Use in Early Pregnancy Not Cause for Alarm

• The risk of non-live birth was 29.7% with continued GLP-1 use versus 27.1% without continuation, a difference not statistically significant
• The study included 1,467 women with type 2 diabetes and found no substantial increase in risks for low/high birth weight or major congenital malformations
• GLP-1 drugs can increase accidental pregnancy risk by improving fertility through weight loss and, particularly with tirzepatide, compromising oral contraceptive absorption

GLP-1 Pregnancy Exposure Summary

Key Findings

A Harvard T.H. Chan School of Public Health study analyzing 3,572 pregnancies provides reassurance about unintentional GLP-1 drug exposure during early pregnancy. The research examined women taking GLP-1 medications before conception, including 1,467 with type 2 diabetes.

Critical Data Points

The study found no statistically significant difference in non-live birth risks between women who continued GLP-1 drugs into the first trimester (29.7%) versus those who discontinued (27.1%). Additionally, continued use showed no substantial increase in risks for low/high birth weight or major congenital malformations, though estimates were imprecise.

Companies and Products

• Novo Nordisk: Semaglutide (Ozempic, Wegovy)
• Eli Lilly: Tirzepatide (Zepbound, Mounjaro)

Clinical Context

GLP-1 drugs are not recommended during pregnancy due to unknown fetal safety and concerning animal studies. Current guidelines advise discontinuing these medications 1-2 months before pregnancy. However, accidental exposure is increasingly common as:

• GLP-1 use among reproductive-age women grows
• These drugs can improve fertility in obese women through weight reduction
• Tirzepatide specifically compromises oral contraceptive absorption, increasing accidental pregnancy risk

Market Implications

This study, published in Annals of Internal Medicine, addresses growing safety concerns as GLP-1 medications expand beyond diabetes into widespread obesity treatment. While researchers emphasize the findings cannot change current recommendations, the reassuring data may reduce liability concerns and support continued market expansion among women of childbearing age.

Senior author Dr. Sonia Hernandez-Diaz stressed that pregnant women should still follow label guidance and clinician advice, but those with unintentional early exposure need not panic.